These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36194495)

  • 1. Lessons Learned, Challenges Taken, and Actions Made for "Precision" Immunohistochemistry. Analysis and Perspectives From the NordiQC Proficiency Testing Program.
    Nielsen S; Bzorek M; Vyberg M; Røge R
    Appl Immunohistochem Mol Morphol; 2023 Aug; 31(7):452-458. PubMed ID: 36194495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proficiency testing in immunohistochemistry--experiences from Nordic Immunohistochemical Quality Control (NordiQC).
    Vyberg M; Nielsen S
    Virchows Arch; 2016 Jan; 468(1):19-29. PubMed ID: 26306713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China.
    Pu T; Shui R; Shi J; Liang Z; Yang W; Bu H; Li Q; Zhang Z;
    BMC Cancer; 2019 Oct; 19(1):978. PubMed ID: 31640622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A National Quality Assurance program for breast immunohistochemistry: an Italian perspective.
    Guadagno E; De Rosa G; Nappi O
    Pathologica; 2018 Sep; 110(2):83-91. PubMed ID: 30546143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External Quality Assurance Helps Improve Infrastructure for Testing Breast Biomarkers Across a Lower- and Middle-Income Country: Our Experience With Breast Biomarker Testing in the National Cancer Grid External Quality Assurance System in India.
    Shet T; Tambe S; Phadatare N; Panjwani P; Desai S; Sengar M; Pramesh CS
    Arch Pathol Lab Med; 2024 Sep; 148(9):1028-1034. PubMed ID: 38153249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current issues in ER and HER2 testing by IHC in breast cancer.
    Gown AM
    Mod Pathol; 2008 May; 21 Suppl 2():S8-S15. PubMed ID: 18437174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program.
    Francis GD; Dimech M; Giles L; Hopkins A
    J Clin Pathol; 2007 Nov; 60(11):1277-83. PubMed ID: 17259294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Assessment of Immunohistochemistry Laboratory Performance by Measuring Analytic Response Curves and Limits of Detection.
    Sompuram SR; Vani K; Schaedle AK; Balasubramanian A; Bogen SA
    Arch Pathol Lab Med; 2018 Jul; 142(7):851-862. PubMed ID: 29595317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External quality assessment for immunohistochemistry: experiences from NordiQC.
    Nielsen S
    Biotech Histochem; 2015 Jul; 90(5):331-40. PubMed ID: 25901597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation.
    Keppens C; Dequeker EM; Pauwels P; Ryska A; 't Hart N; von der Thüsen JH
    Virchows Arch; 2021 May; 478(5):827-839. PubMed ID: 33275169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program.
    Hung T; Wolber R; Garratt J; Kalloger S; Gilks CB
    Pathology; 2010 Dec; 42(7):637-42. PubMed ID: 21080872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial Intelligence Algorithms to Assess Hormonal Status From Tissue Microarrays in Patients With Breast Cancer.
    Shamai G; Binenbaum Y; Slossberg R; Duek I; Gil Z; Kimmel R
    JAMA Netw Open; 2019 Jul; 2(7):e197700. PubMed ID: 31348505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 Immunohistochemistry in Invasive Micropapillary Breast Carcinoma: Complete Assessment of an Incomplete Pattern.
    Perron M; Wen HY; Hanna MG; Brogi E; Ross DS
    Arch Pathol Lab Med; 2021 Aug; 145(8):979-987. PubMed ID: 33212478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
    Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
    Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
    Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
    Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proficiency testing of immunohistochemical biomarker assays in breast cancer.
    Wasielewski Rv; Hasselmann S; Rüschoff J; Fisseler-Eckhoff A; Kreipe H
    Virchows Arch; 2008 Dec; 453(6):537-43. PubMed ID: 18958494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution.
    Oluwasola AO; Malaka D; Khramtsov AI; Ikpatt OF; Odetunde A; Adeyanju OO; Sveen WE; Falusi AG; Huo D; Olopade OI
    Ann Diagn Pathol; 2013 Dec; 17(6):526-30. PubMed ID: 24095629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
    Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
    Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.
    O'Malley FP; Thomson T; Julian J; Have C; Cosby R; Gelmon K; Andrulis I; Whelan T
    Arch Pathol Lab Med; 2008 Jan; 132(1):61-5. PubMed ID: 18181675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
    Reddy JC; Reimann JD; Anderson SM; Klein PM
    Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.